StockNews.AI
URGN
StockNews.AI
91 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

1. Pomerantz LLP is investigating UroGen Pharma for potential securities fraud. 2. FDA criticized UroGen's Envision trial for lack of control group. 3. UGN-102's primary endpoints are deemed difficult to interpret by FDA. 4. UroGen's stock fell 25.79% after FDA briefing document release.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price highlights severe market reactions to FDA warnings.

How important is it?

The investigation and FDA's feedback pose serious risks to UroGen's market position.

Why Short Term?

Immediate investor concerns over FDA feedback may affect URGN's stock in the coming weeks.

Related Companies

PFEAMGNJNJ
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether UroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 16, 2025, the U.S. Food and Drug Administration ("FDA") posted a briefing document for the Oncologic Drugs Advisory Committee meeting, scheduled for May 21, 2025, to discuss the New Drug Application for UroGen's bladder cancer drug UGN-102 (mitomycin). Among other things, the briefing document said that because the Company's Envision trial lacked a concurrent control arm, the trial's primary endpoints of complete response and duration of response are difficult to interpret. The FDA further stated that it recommended a randomized trial design "several times" to UroGen to assuage these concerns.  On this news, UroGen's stock price fell $2.54 per share, or 25.79%, to close at $7.31 per share on May 16, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News